胸腺肽α1单用及联合干扰素-α1b治疗慢性乙型肝炎疗效观察

A comparative trial of thymosin α1 vs. thymosin α1 combined with interferon α1b in the treatment of chronic hepatitis B

目的研究单用胸腺肽α１（Ｔα１）及联合应用干扰素（ＩＦＮ）对慢性乙型肝炎（ＣＨＢ）的治疗作用。方法３６例ＣＨＢ患者随机分为Ａ、Ｂ两组，Ａ组采用Ｔα１和ＩＦＮ联合治疗；Ｂ组单用Ｔα１，疗程均为６个月。结果治疗后６月时ＡＬＴ水平在Ａ、Ｂ两组分别下降至（７２．１±４．７７）Ｕ／Ｌ和（７３．７±３７．９）Ｕ／Ｌ，较治疗前（２２６．７±２１９．４）Ｕ／Ｌ和（１７０．１±１６５．６）Ｕ／Ｌ明显下降（Ｐ＝０．００２７和０．０００３）。ＨＢＶＤＮＡ水平在Ａ、Ｂ两组分别下降到（１３０±２８３）ｍＥｑ／ｍｌ和（３７３±８２５）ｍＥｑ／ｍｌ，较治疗前（８０７±１２２２）ｍＥｑ／ｍｌ和（８８３±１４３８）ｍＥｑ／ｍｌ明显下降（Ｐ＝０．００１９和０．０１９）。治疗后６月时，具有ＡＬＴ完全反应者，Ａ组和Ｂ组分别为８例（４４％）和９例（５０％），具有ＨＢＶ清除反应者Ａ组为８例（４４．４％），Ｂ组为７例（３８．８％）。

Objective To observe the efficacy and safety of Tα1 vs. Tα1 combined with IFN α in the treatment of chronic hepatitis B. Methods Thirty eight patients with chronic hepatitis B were randomly divided into group A and B. Patients in both groups received Tα1 for six months. However, patients in group A received IFN α coincidently for six months. Results At the end of treatment, ALT level decreased in the patients of both group A and group B( P =0.0043 and P =0.0036, respectively), which decreased 96.6±38.3IU/L( P =0.00189) in group A and 81.93±56.39IU/L in group B respectively. HBV DNA level decreased 130±283 mEq/ml( P =0.0019) in group A and 373±825 mEq/ml in group B( P =0.019).Conclusion The Tα1 or Tα1 combined with IFN α is efficient to treat patients with chronic hepatitis B.